9.33
-0.0348(-0.37%)
Currency In USD
Address
51 West 52nd Street
New York City, NY 10019
United States of America
Phone
844 689 3939
Website
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
42
First IPO Date
January 29, 2018
| Name | Title | Pay | Year Born |
| Dr. Christopher U. Missling M.B.A., M.S., Ph.D. | President, Chief Executive Officer, Secretary & Director | 856,100 | 1966 |
| Ms. Sandra Boenisch CPA, CGA | Principal Financial Officer & Treasurer | 209,527 | 1981 |
| Dr. Juan Carlos Lopez-Talavera M.D., Ph.D. | Senior Vice President & Head of Research and Development | 0 | N/A |
| Dr. Kun Jin Ph.D. | Head of Biostatistics | 0 | N/A |
| Dr. Terrie Kellmeyer Ph.D. | Senior Vice President of Clinical Development | 0 | N/A |
| Dr. Edward R Hammond M.D., M.P.H., Ph.D. | Chief Medical Officer | 0 | N/A |
| Dr. Adebayo Laniyonu Ph.D. | Senior Vice President of Nonclinical Development | 0 | N/A |
| Clint Tomlinson | Vice President of Corporate | 0 | N/A |
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.